Fig. 1From: TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinomaOverall survival of patients in three groupsmOS: Control group,12.2 months (95% CI 11.2–13.3 months); Entecavir group,17.3 months (95% CI 15.6–18.9 months); Tenofovir group,22.5 months (95% CI 20.5–24.4 months)Back to article page